-
2
-
-
0035902456
-
Current concepts of the pathogenesis of the acute coronary syndrome
-
Libby P: Current concepts of the pathogenesis of the acute coronary syndrome. Circulation 104, 365-372 (2001).
-
(2001)
Circulation
, vol.104
, pp. 365-372
-
-
Libby, P.1
-
3
-
-
35448971466
-
-
on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the redefnition of myocardial infarction: Universal defnition of myocardial infarction
-
Thygessen K, Alpert JS, White HD; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the redefnition of myocardial infarction: Universal defnition of myocardial infarction. Eur. Heart J. 28, 2525-2538 (2007).
-
(2007)
Eur. Heart J.
, vol.28
, pp. 2525-2538
-
-
Thygessen, K.1
Alpert, J.S.2
White, H.D.3
-
4
-
-
57349189353
-
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology
-
Van de Werf F, Bax J, Betriu A et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 29, 2909-2945 (2008).
-
(2008)
Eur. Heart J.
, vol.29
, pp. 2909-2945
-
-
Van De Werf, F.1
Bax, J.2
Betriu, A.3
-
5
-
-
68849107287
-
Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction
-
Rabbani LE, Iyengar S, Dangas GD et al.: Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. J. Interv. Cardiol. 22, 378-384 (2009).
-
(2009)
J. Interv. Cardiol.
, vol.22
, pp. 378-384
-
-
Rabbani, L.E.1
Iyengar, S.2
Dangas, G.D.3
-
6
-
-
70449514842
-
Coronary microembolization: From bedside to bench and back to bedside
-
Heusch G, Kleinbongard P, Böse D et al.: Coronary microembolization: from bedside to bench and back to bedside. Circulation 120, 1822-1836 (2009).
-
(2009)
Circulation
, vol.120
, pp. 1822-1836
-
-
Heusch, G.1
Kleinbongard, P.2
Böse, D.3
-
7
-
-
65249135889
-
Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction
-
Fokkema ML, Vlaar PJ, Svilaas T et al.: Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. Eur. Heart J. 30, 908-915 (2009).
-
(2009)
Eur. Heart J.
, vol.30
, pp. 908-915
-
-
Fokkema, M.L.1
Vlaar, P.J.2
Svilaas, T.3
-
8
-
-
20244377701
-
Guidelines for percutaneous coronary interventions
-
DOI 10.1093/eurheartj/ehi138
-
Silber S, Albertsson P, Avillés FF et al.: Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J. 26, 804-847 (2005). (Pubitemid 40547082)
-
(2005)
European Heart Journal
, vol.26
, Issue.8
, pp. 804-847
-
-
Silber, S.1
Albertsson, P.2
Aviles, F.F.3
Camici, P.G.4
Colombo, A.5
Hamm, C.6
Jorgensen, E.7
Marco, J.8
Nordrehaug, J.-E.9
Ruzyllo, W.10
Urban, P.11
Stone, G.W.12
Wijns, W.13
-
9
-
-
0023805341
-
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
-
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
-
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 349, 349-360 (1988).
-
(1988)
Lancet
, vol.349
, pp. 349-360
-
-
-
10
-
-
9144270451
-
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
-
Patrono C, Bachmann F, Baigent C et al.: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur. Heart J. 25, 166-181 (2004).
-
(2004)
Eur. Heart J.
, vol.25
, pp. 166-181
-
-
Patrono, C.1
Bachmann, F.2
Baigent, C.3
-
11
-
-
77956164467
-
A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial
-
Presented at: Barcelona, Spain, 29 August-2 September
-
Mehta SR, Van de Werf F: A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: results of the CURRENT OASIS 7 Trial. Presented at: Congress of the European Society of Cardiology. Barcelona, Spain, 29 August-2 September, 2009.
-
(2009)
Congress of the European Society of Cardiology
-
-
Mehta, S.R.1
Van De Werf, F.2
-
12
-
-
33747874088
-
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Infammation and Ongoing Necrosis) trial
-
Montalescot G, Sideris G, Meuleman C et al.: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Infammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48, 931-938 (2006).
-
(2006)
J. Am. Coll. Cardiol.
, vol.48
, pp. 931-938
-
-
Montalescot, G.1
Sideris, G.2
Meuleman, C.3
-
13
-
-
24644495673
-
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fbrinolytics: The PCI-CLARITY study
-
Sabatine MS, Cannon CP, Gibson CM et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fbrinolytics: the PCI-CLARITY study. JAMA 294, 1224-1232 (2005).
-
(2005)
JAMA
, vol.294
, pp. 1224-1232
-
-
Sabatine, M.S.1
Cannon, C.P.2
Gibson, C.M.3
-
14
-
-
33750901162
-
Acute Coronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice
-
Zeymer U, Gitt AK, Junger C et al.: Acute Coronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur. Heart J. 27, 2661-2666 (2006).
-
(2006)
Eur. Heart J.
, vol.27
, pp. 2661-2666
-
-
Zeymer, U.1
Gitt, A.K.2
Junger, C.3
-
15
-
-
0035908781
-
Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
-
Mehta SR, Yusuf S, Peters RJ et al.: Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
-
(2001)
Lancet
, vol.358
, pp. 527-533
-
-
Mehta, S.R.1
Yusuf, S.2
Peters, R.J.3
-
16
-
-
0037145863
-
Clopidogrel for the reduction of events during observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial
-
Steinhubl SR, Berger PB, Mann JT III et al.: Clopidogrel for the reduction of events during observation: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial. JAMA 288, 2411-2420 (2002).
-
(2002)
JAMA
, vol.288
, pp. 2411-2420
-
-
Steinhubl, S.R.1
Berger, P.B.2
Mann Iii, J.T.3
-
17
-
-
67849083515
-
Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction
-
Fefer P, Hod H, Hammerman H et al.: Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am. J. Cardiol. 104, 514-518 (2009).
-
(2009)
Am. J. Cardiol.
, vol.104
, pp. 514-518
-
-
Fefer, P.1
Hod, H.2
Hammerman, H.3
-
18
-
-
56949093392
-
Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy
-
Mehta SR, Bassand JP, Chrolavicius S et al.: Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am. Heart J. 156, 1080-1088 (2008).
-
(2008)
Am. Heart J.
, vol.156
, pp. 1080-1088
-
-
Mehta, S.R.1
Bassand, J.P.2
Chrolavicius, S.3
-
19
-
-
53449098101
-
Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: The Reload with Clopidogrel before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study
-
Collet JP, Silvain J, Landivier A et al.: Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 118, 1225-1233 (2008).
-
(2008)
Circulation
, vol.118
, pp. 1225-1233
-
-
Collet, J.P.1
Silvain, J.2
Landivier, A.3
-
20
-
-
27744516843
-
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial
-
Von Beckerath N, Taubert D, Pogatsa-Murray G et al.: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112, 2946-2950 (2005).
-
(2005)
Circulation
, vol.112
, pp. 2946-2950
-
-
Von Beckerath, N.1
Taubert, D.2
Pogatsa-Murray, G.3
-
21
-
-
37349111065
-
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
-
Wiviott SD, Trenk D, Frelinger AL et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116, 2923-2932 (2007).
-
(2007)
Circulation
, vol.116
, pp. 2923-2932
-
-
Wiviott, S.D.1
Trenk, D.2
Frelinger, A.L.3
-
22
-
-
74249088972
-
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome
-
Montalescot G, Sideris G, Cohen R et al.: Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. Thromb. Haemost. 103, 213-223 (2010).
-
(2010)
Thromb. Haemost.
, vol.103
, pp. 213-223
-
-
Montalescot, G.1
Sideris, G.2
Cohen, R.3
-
23
-
-
67651173161
-
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
-
Michelson AD, Frelinger AL III, Braunwald E et al.: Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J. 30, 1753-1763 (2009).
-
(2009)
Eur. Heart J.
, vol.30
, pp. 1753-1763
-
-
Michelson, A.D.1
Frelinger Iii, A.L.2
Braunwald, E.3
-
24
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
DOI 10.1056/NEJMoa0706482
-
Wiviott SD, Braunwald E, McCabe CH et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.20
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
Montalescot, G.4
Ruzyllo, W.5
Gottlieb, S.6
Neumann, F.-J.7
Ardissino, D.8
De Servi, S.9
Murphy, S.A.10
Riesmeyer, J.11
Weerakkody, G.12
Gibson, C.M.13
Antman, E.M.14
-
25
-
-
55949103494
-
Greater clinical beneft of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38
-
Wiviott SD, Braunwald E, Angiolillo DJ et al.: Greater clinical beneft of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation 118, 1626-1636 (2008).
-
(2008)
Circulation
, vol.118
, pp. 1626-1636
-
-
Wiviott, S.D.1
Braunwald, E.2
Angiolillo, D.J.3
-
26
-
-
60649112469
-
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial
-
Montalescot G, Wiviott SD, Braunwald E et al.: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723-731 (2009).
-
(2009)
Lancet
, vol.373
, pp. 723-731
-
-
Montalescot, G.1
Wiviott, S.D.2
Braunwald, E.3
-
27
-
-
70450199115
-
2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the
-
American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
-
Kushner FG, Hand M, Smith SC Jr et al.: 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 54, 2205-2241 (2009).
-
(2009)
J. Am. Coll. Cardiol.
, vol.54
, pp. 2205-2241
-
-
Kushner, F.G.1
Hand, M.2
Smith Jr., S.C.3
-
28
-
-
73949112820
-
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
-
Gurbel PA, Bliden KP, Butler K et al.: Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120, 2577-2585 (2009).
-
(2009)
Circulation
, vol.120
, pp. 2577-2585
-
-
Gurbel, P.A.1
Bliden, K.P.2
Butler, K.3
-
29
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
Wallentin L, Becker RC, Budaj A et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
-
30
-
-
78349260032
-
-
Presented at: AHA Orlando, FL, USA, 14-18 Nov
-
Steg G, James S, Akerblom A et al.: Comparison of ticagrelor, the frst reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results from the PLATelet inhibition and patient Outcomes (PLATO) trial. Presented at: AHA Orlando, FL, USA, 14-18 Nov, 2009.
-
(2009)
Comparison of Ticagrelor, the Frst Reversible Oral P2Y12 Receptor Antagonist, with Clopidogrel in Patients with Acute Coronary Syndromes: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Trial
-
-
Steg, G.1
James, S.2
Akerblom, A.3
-
31
-
-
33344464928
-
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial
-
E1-689. E10 2006
-
Greenbaum AB, Grines CL, Bittl JA et al.: Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J. 151, 689. E1-689.E10 (2006).
-
Am. Heart J.
, vol.151
, pp. 689
-
-
Greenbaum, A.B.1
Grines, C.L.2
Bittl, J.A.3
-
32
-
-
71849087338
-
Platelet inhibition with cangrelor in patients undergoing PCI
-
Harrington RA, Stone GW, McNulty S et al.: Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361, 2318-2329 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 2318-2329
-
-
Harrington, R.A.1
Stone, G.W.2
McNulty, S.3
-
33
-
-
67650761110
-
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
-
Chen KY, Rha SW, Li YJ et al.: Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 119, 3207-3214 (2009).
-
(2009)
Circulation
, vol.119
, pp. 3207-3214
-
-
Chen, K.Y.1
Rha, S.W.2
Li, Y.J.3
-
34
-
-
62949165644
-
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study
-
Han Y, Li Y, Wang S et al.: Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am. Heart J. 157, 733-739 (2009).
-
(2009)
Am. Heart J.
, vol.157
, pp. 733-739
-
-
Han, Y.1
Li, Y.2
Wang, S.3
-
35
-
-
44349138210
-
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
-
Biondi-Zoccai GG, Lotrionte M, Anselmino M et al.: Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am. Heart J. 155, 1081-1089 (2008).
-
(2008)
Am. Heart J.
, vol.155
, pp. 1081-1089
-
-
Biondi-Zoccai, G.G.1
Lotrionte, M.2
Anselmino, M.3
-
36
-
-
60749114799
-
Interindividual variability in the response to oral antiplatelet drugs: A position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
-
Kuliczkowski W, Witkowski A, Polonski L et al.: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 30, 426-435 (2009).
-
(2009)
Eur. Heart J.
, vol.30
, pp. 426-435
-
-
Kuliczkowski, W.1
Witkowski, A.2
Polonski, L.3
-
37
-
-
34447576539
-
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
-
Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154, 221-231 (2007).
-
(2007)
Am. Heart J.
, vol.154
, pp. 221-231
-
-
Snoep, J.D.1
Hovens, M.M.2
Eikenboom, J.C.3
Van Der Bom, J.G.4
Jukema, J.W.5
Huisman, M.V.6
-
38
-
-
34447503098
-
Association of laboratory-defned aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis
-
Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV: Association of laboratory-defned aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167, 1593-1599 (2007).
-
(2007)
Arch. Intern. Med.
, vol.167
, pp. 1593-1599
-
-
Snoep, J.D.1
Hovens, M.M.2
Eikenboom, J.C.3
Van Der Bom, J.G.4
Huisman, M.V.5
-
39
-
-
35348816934
-
Anti platelet therapy after implantation of drug-eluting stents: Duration, resistance, alternatives, and management of surgical patients
-
Gurbel PA, DiChiara J, Tantry US: Anti platelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am. J. Cardiol. 100(8B), M18-M25 (2007).
-
(2007)
Am. J. Cardiol.
, vol.100
, Issue.8 B
-
-
Gurbel, P.A.1
Dichiara, J.2
Tantry, U.S.3
-
40
-
-
77952075376
-
Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis
-
Sof F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF: Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb. Haemost. 103, 841-848 (2010).
-
(2010)
Thromb. Haemost.
, vol.103
, pp. 841-848
-
-
Sof, F.1
Marcucci, R.2
Gori, A.M.3
Giusti, B.4
Abbate, R.5
Gensini, G.F.6
-
41
-
-
41249093357
-
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study
-
Bonello L, Camoin-Jau L, Arques S et al.: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404-1411 (2008).
-
(2008)
J. Am. Coll. Cardiol.
, vol.51
, pp. 1404-1411
-
-
Bonello, L.1
Camoin-Jau, L.2
Arques, S.3
-
42
-
-
77149139817
-
High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients
-
Tavassoli N, Voisin S, Carrie D et al.: High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am. J. Cardiovasc. Drugs 10, 29-35 (2010).
-
(2010)
Am. J. Cardiovasc. Drugs
, vol.10
, pp. 29-35
-
-
Tavassoli, N.1
Voisin, S.2
Carrie, D.3
-
43
-
-
58249135635
-
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study
-
Collet JP, Hulot JS, Pena A et al.: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
-
(2009)
Lancet
, vol.373
, pp. 309-317
-
-
Collet, J.P.1
Hulot, J.S.2
Pena, A.3
-
44
-
-
58749090547
-
Genetic determinants of response to clopidogrel and cardiovascular events
-
Simon T, Verstuyft C, Mary-Krause M et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 363-375
-
-
Simon, T.1
Verstuyft, C.2
Mary-Krause, M.3
-
45
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
Mega JL, Close SL, Wiviott SD et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2008).
-
(2008)
N. Engl. J. Med.
, vol.360
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
46
-
-
79957472412
-
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: A meta-analysis
-
DOI: 10.1038/tpj.2010.21 Epub ahead of print
-
Sof F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF: Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. DOI: 10.1038/tpj.2010.21 (2010) (Epub ahead of print).
-
(2010)
Pharmacogenomics J.
-
-
Sof, F.1
Giusti, B.2
Marcucci, R.3
Gori, A.M.4
Abbate, R.5
Gensini, G.F.6
-
47
-
-
77949894946
-
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
-
Giusti B, Gori AM, Marcucci R, Abbate R. Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert. Opin. Drug Metab. Toxicol. 6, 393-407 (2010).
-
(2010)
Expert. Opin. Drug Metab. Toxicol.
, vol.6
, pp. 393-407
-
-
Giusti, B.1
Gori, A.M.2
Marcucci, R.3
Abbate, R.4
-
48
-
-
66349133650
-
Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
-
Mega JL, Close SL, Wiviott SD et al.: Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553-2560 (2009).
-
(2009)
Circulation
, vol.119
, pp. 2553-2560
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
49
-
-
77950508416
-
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies
-
The RESPOND Study
-
Gurbel PA, Bliden KP, Butler K et al.: Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies. The RESPOND Study. Circulation 121, 1188-1199 (2010).
-
(2010)
Circulation
, vol.121
, pp. 1188-1199
-
-
Gurbel, P.A.1
Bliden, K.P.2
Butler, K.3
-
50
-
-
73149118496
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: Frst experience in patients
-
Gurbel PA, Bliden KP, Antonino MJ et al.: The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: frst experience in patients. J. Thromb. Haemost. 8, 43-53 (2010).
-
(2010)
J. Thromb. Haemost.
, vol.8
, pp. 43-53
-
-
Gurbel, P.A.1
Bliden, K.P.2
Antonino, M.J.3
-
51
-
-
62549101321
-
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance) randomized study
-
Jeong YH, Lee SW, Choi BR et al.: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol. 53, 1101-1109 (2009).
-
(2009)
J. Am. Coll. Cardiol.
, vol.53
, pp. 1101-1109
-
-
Jeong, Y.H.1
Lee, S.W.2
Choi, B.R.3
-
52
-
-
73549106603
-
Evaluation of platelet inhibition by tirofban in patients stratifed according to aspirin and clopidogrel responsiveness: The 3T/2R (tailoring treatment with tirofban in patients showing resistance to aspirin and/or resistance to clopidogrel)
-
Campo G, Valgimigli M, Frangione A et al.: Evaluation of platelet inhibition by tirofban in patients stratifed according to aspirin and clopidogrel responsiveness: the 3T/2R (tailoring treatment with tirofban in patients showing resistance to aspirin and/or resistance to clopidogrel). J. Am. Coll. Cardiol. 55, 255-256 (2010).
-
(2010)
J. Am. Coll. Cardiol.
, vol.55
, pp. 255-256
-
-
Campo, G.1
Valgimigli, M.2
Frangione, A.3
-
53
-
-
0034624841
-
Microvascular dysfunction in acute myocardial infarction: Focus on the roles of platelet and infammatory mediators in the no-refow phenomenon
-
Michaels AD, Gibson CM, Baron HV: Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and infammatory mediators in the no-refow phenomenon. Am. J. Cardiol. 85, B50-B60 (2000).
-
(2000)
Am. J. Cardiol.
, vol.85
-
-
Michaels, A.D.1
Gibson, C.M.2
Baron, H.V.3
-
54
-
-
10644269830
-
Effcacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: A meta-analysis of randomized, controlled trials
-
de Queiroz Fernandes Araujo JO, Veloso HH, Braga De Paiva JM et al.: Effcacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. Am. Heart J. 148, 937-943 (2004).
-
(2004)
Am. Heart J.
, vol.148
, pp. 937-943
-
-
De Queiroz Fernandes Araujo, J.O.1
Veloso, H.H.2
Braga De Paiva, J.M.3
-
55
-
-
16444368352
-
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials
-
De Luca G, Suryapranata H, Stone GW et al.: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293, 1759-1765 (2005).
-
(2005)
JAMA
, vol.293
, pp. 1759-1765
-
-
De Luca, G.1
Suryapranata, H.2
Stone, G.W.3
-
56
-
-
34548359246
-
Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients' data with long-term follow-up
-
Montalescot G, Antoniucci D, Kastrati A et al.: Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur. Heart J. 28, 443-449 (2007).
-
(2007)
Eur. Heart J.
, vol.28
, pp. 443-449
-
-
Montalescot, G.1
Antoniucci, D.2
Kastrati, A.3
-
57
-
-
0032566404
-
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
-
ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators
-
Brener SJ, Barr LA, Burchenal JE et al.: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98, 734-741 (1998).
-
(1998)
Circulation
, vol.98
, pp. 734-741
-
-
Brener, S.J.1
Barr, L.A.2
Burchenal, J.E.3
-
58
-
-
0035927938
-
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
-
DOI 10.1056/NEJM200106213442503
-
Montalescot G, Barragan P, Wittenberg O et al.: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 344, 1895-1903 (2001). (Pubitemid 32553358)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.25
, pp. 1895-1903
-
-
Montalescot, G.1
Barragan, P.2
Wittenberg, O.3
Ecollan, P.4
Elhadad, S.5
Villain, P.6
Boulenc, J.-M.7
Morice, M.-C.8
Maillard, L.9
Pansieri, M.10
Choussat, R.11
Pinton, P.12
-
59
-
-
19244387281
-
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
-
Neumann FJ, Kastrati A, Schmitt C et al.: Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J. Am. Coll. Cardiol. 35, 915-921 (2000).
-
(2000)
J. Am. Coll. Cardiol.
, vol.35
, pp. 915-921
-
-
Neumann, F.J.1
Kastrati, A.2
Schmitt, C.3
-
60
-
-
0141765874
-
Benefts and risks of abciximab use in primary angioplasty for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
-
Tcheng JE, Kandzari DE, Grines CL et al.: Benefts and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 108, 1316-1323 (2003).
-
(2003)
Circulation
, vol.108
, pp. 1316-1323
-
-
Tcheng, J.E.1
Kandzari, D.E.2
Grines, C.L.3
-
61
-
-
4444384038
-
Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: A prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone
-
Antoniucci D, Migliorini A, Parodi G et al.: Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 109, 1704-1706 (2004).
-
(2004)
Circulation
, vol.109
, pp. 1704-1706
-
-
Antoniucci, D.1
Migliorini, A.2
Parodi, G.3
-
62
-
-
65549139808
-
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading. A randomized double-blind trial
-
Mehilli J, Kastrati A, Schulz S et al.: Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading. A randomized double-blind trial. Circulation 119, 1933-1940 (2009).
-
(2009)
Circulation
, vol.119
, pp. 1933-1940
-
-
Mehilli, J.1
Kastrati, A.2
Schulz, S.3
-
63
-
-
70349630641
-
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
-
Mehran R, Lansky AJ, Witzenbichler B et al.: Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374, 1149-1159 (2009).
-
(2009)
Lancet
, vol.374
, pp. 1149-1159
-
-
Mehran, R.1
Lansky, A.J.2
Witzenbichler, B.3
-
64
-
-
67650925419
-
Infuence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality
-
Witkowski A, Maciejewski P, Wasek W et al.: Infuence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality Eur. Heart J. 30, 1736-1743 (2009).
-
(2009)
Eur. Heart J.
, vol.30
, pp. 1736-1743
-
-
Witkowski, A.1
MacIejewski, P.2
Wasek, W.3
-
65
-
-
72949090599
-
Risk profle and benefts from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-regression analysis of randomized trials
-
De Luca G, Navarese E, Marino P. Risk profle and benefts from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur. Heart J. 30, 2705-2713 (2009).
-
(2009)
Eur. Heart J.
, vol.30
, pp. 2705-2713
-
-
De Luca, G.1
Navarese, E.2
Marino, P.3
-
66
-
-
77951719621
-
Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting
-
Jeremias A, Vasu S, Gruberg L, Kastrati A, Stone GW, Brown DL: Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Catheter. Cardiovasc. Interv. 75, 895-902 (2010).
-
(2010)
Catheter. Cardiovasc. Interv.
, vol.75
, pp. 895-902
-
-
Jeremias, A.1
Vasu, S.2
Gruberg, L.3
Kastrati, A.4
Stone, G.W.5
Brown, D.L.6
-
67
-
-
44249120546
-
Facilitated PCI in patients with ST-elevation myocardial infarction
-
Ellis SG, Tendera M, de Belder MA et al.: Facilitated PCI in patients with ST-elevation myocardial infarction. N. Engl. J. Med. 358, 2205-2217 (2008).
-
(2008)
N. Engl. J. Med.
, vol.358
, pp. 2205-2217
-
-
Ellis, S.G.1
Tendera, M.2
De Belder, M.A.3
-
68
-
-
75149170908
-
Primary percutaneous coronary angioplasty with and without eptifbatide in ST-segment elevation myocardial infarction: A safety and effcacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST)
-
Le May MR, Wells GA, Glover CA et al.: Primary percutaneous coronary angioplasty with and without eptifbatide in ST-segment elevation myocardial infarction: a safety and effcacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ. Cardiovasc. Interv. 2, 330-338 (2009).
-
(2009)
Circ. Cardiovasc. Interv.
, vol.2
, pp. 330-338
-
-
Le May, M.R.1
Wells, G.A.2
Glover, C.A.3
-
69
-
-
49149128492
-
Prehospital initiation of tirofban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial
-
Van't Hof AW, Ten BJ, Heestermans T et al. Prehospital initiation of tirofban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 372, 537-546, 2008).
-
(2008)
Lancet
, vol.372
, pp. 537-546
-
-
Van'T Hof, A.W.1
Ten, B.J.2
Heestermans, T.3
-
70
-
-
38349188423
-
The relative safety and effcacy of abciximab and eptifbatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention
-
Gurm HS, Smith DE, Collins JS et al.: The relative safety and effcacy of abciximab and eptifbatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J. Am. Coll. Cardiol. 51, 529-535 (2008).
-
(2008)
J. Am. Coll. Cardiol.
, vol.51
, pp. 529-535
-
-
Gurm, H.S.1
Smith, D.E.2
Collins, J.S.3
-
71
-
-
42249090036
-
Comparison of angioplasty with infusion of tirofban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial
-
Valgimigli M, Campo G, Percoco G et al.: Comparison of angioplasty with infusion of tirofban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299, 1788-1799 (2008).
-
(2008)
JAMA
, vol.299
, pp. 1788-1799
-
-
Valgimigli, M.1
Campo, G.2
Percoco, G.3
-
72
-
-
61349143698
-
Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofban (from the Facilitated Angioplasty with Tirofban or Abciximab [FATA] Trial)
-
Taglieri N, Saia F, Guiducci V et al.: Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofban (from the Facilitated Angioplasty with Tirofban or Abciximab [FATA] Trial). Am. J. Cardiol. 103, 785-790 (2009).
-
(2009)
Am. J. Cardiol.
, vol.103
, pp. 785-790
-
-
Taglieri, N.1
Saia, F.2
Guiducci, V.3
-
73
-
-
70450141566
-
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: A meta-analysis of contemporary randomized controlled trials
-
Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER: A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ. Cardiovasc. Interv. 2, 230-236 (2009)
-
(2009)
Circ. Cardiovasc. Interv.
, vol.2
, pp. 230-236
-
-
Gurm, H.S.1
Tamhane, U.2
Meier, P.3
Grossman, P.M.4
Chetcuti, S.5
Bates, E.R.6
-
74
-
-
50949102097
-
Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial
-
Thiele H, Schindler K, Friedenberger J et al.: Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118, 49-57 (2008).
-
(2008)
Circulation
, vol.118
, pp. 49-57
-
-
Thiele, H.1
Schindler, K.2
Friedenberger, J.3
-
75
-
-
70349417896
-
Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-effects on soluble CD40 ligand concentrations
-
Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P et al.: Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-effects on soluble CD40 ligand concentrations. Atherosclerosis 206, 523-527 (2009).
-
(2009)
Atherosclerosis
, vol.206
, pp. 523-527
-
-
Dominguez-Rodriguez, A.1
Abreu-Gonzalez, P.2
Avanzas, P.3
-
76
-
-
70449686719
-
Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: Rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
-
Gu YL, Fokkema ML, Kampinga MA et al.: Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration. Trials 10, 90 (2009).
-
(2009)
Trials
, vol.10
, pp. 90
-
-
Gu, Y.L.1
Fokkema, M.L.2
Kampinga, M.A.3
-
77
-
-
77953281484
-
A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): Trial study design and rationale
-
Sardella G, Sangiorgi GM, Mancone M et al.: A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale. J. Cardiovasc. Med. 11, 529-535 (2010).
-
(2010)
J. Cardiovasc. Med.
, vol.11
, pp. 529-535
-
-
Sardella, G.1
Sangiorgi, G.M.2
Mancone, M.3
-
78
-
-
77149179733
-
Intracoronary Eptifbatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: The Intracoronary Eptifbatide (ICE) trial
-
Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM: Intracoronary Eptifbatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifbatide (ICE) trial. Circulation 121, 784-791 (2010).
-
(2010)
Circulation
, vol.121
, pp. 784-791
-
-
Deibele, A.J.1
Jennings, L.K.2
Tcheng, J.E.3
Neva, C.4
Earhart, A.D.5
Gibson, C.M.6
-
79
-
-
52749095514
-
Effect of intracoronary tirofban in patients undergoing percutaneous coronary intervention for acute coronary syndrome
-
Wu TG, Zhao Q, Huang WG et al.: Effect of intracoronary tirofban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ. J. 72, 1605-1609 (2008).
-
(2008)
Circ. J.
, vol.72
, pp. 1605-1609
-
-
Wu, T.G.1
Zhao, Q.2
Huang, W.G.3
|